Alexandre Vamvakides, Ph.D.
Scientific Founder, Chief Scientific Officer, Chairman of Scientific Advisory Board
Dr. Vamvakides has spent 30 years in research, focusing on the therapeutic/pharmacological areas of nootropes, anti-neurodegenerative (anti-Alzheimer’s), anti-epileptic, anti-depressive and prototype molecules. The author of 80+ published scientific papers, he has worked at the Institut National de la Sante et de la Recherche Medicale in Paris, France, University of Athens (Greece), Ciba-Geigy (Basel, Switzerland), Sanofi (Montpellier, France), and many other European research labs for the discovery and development of new concepts in the therapeutic areas of CNS, oncology and inflammatory diseases.

Tangui Nicolas Maurice, Ph.D.
Scientific Advisory Board
Dr. Maurice has spent 15 years in the field of neurosciences, including behavioral and molecular neuropharmacology, sigma receptors, neuropeptides, neurosteroids, neurotrophic factors, normal/pathological aging models for Alzheimer’s and related disorders, and behavioral phenotyping of rodent models. Dr. Maurice is a researcher at the Institut national de la sante et de la recherche medicale (INSERM) U710 at Montpellier. He has also held research positions at the Centre National de la Recherche Scientifique (CNRS), INSERM U336, the department of neuropsychopharmacology and hospital pharmacy at Meijo University (Nagoya, Japan), and Jouveinal Research Institute (Fresnes, France).

Paul Aisen, MD
Scientific Advisory Board – Clinical Expert
Dr. Aisen is a leading clinician and researcher in Alzheimer’s disease clinical trials and is on the faculty of the University of California, San Diego (UCSD) School of Medicine’s Department of Neurosciences. His primary research interests focus on the development of new strategies for the treatment of Alzheimer’s disease. Since 2007, Dr. Aisen has been Director of the Alzheimer’s Disease Cooperative Study, a consortium funded by the National Institute on Aging (NIA) to develop assessment instruments and conduct clinical trials. Dr. Aisen is Associate Editor of Alzheimer’s Research and Therapy, a major international peer-reviewed journal, and sits on the editorial board of BMC Medicine. He has published more than 180 peer-reviewed papers.

Rachelle Doody, MD, PhD
Scientific Advisory Board – Clinical Expert
Dr. Doody is the Effie Marie Cain Chair in Alzheimer’s Disease Research and Professor of Neurology at Baylor College of Medicine, where she directs the Alzheimer’s Disease and Memory Disorders Center (ADMDC). The ADMDC was involved in the development of all five of the commercially available, FDA-approved drugs for Alzheimer’s disease, and was the lead site for the development of the most widely prescribed Alzheimer’s disease drug worldwide. She received a B.A. from Rice University, a M.D. from Baylor College of Medicine, and completed internship and residency training at the Royal Victoria Hospital and Montreal Neurologic Institute in Montreal, and at Baylor College of Medicine. Dr. Doody has a Ph.D. in Cognitive Anthropology from Rice University where she studied the brain and language. She has published over 135 original articles, most of which deal with the diagnosis, progression, or treatment of Alzheimer’s Disease. She has received multiple research grants, including a Zenith Award from the National Alzheimer’s Association, and conducted numerous clinical trials of Alzheimer’s Disease therapies. She participates in National and International collaborative efforts, review boards, and advisory boards including Steering Committees for NIH AD Cooperative Study and AD Neuroimaging Initiative. Current research interests include studies to understand and model the progression of Alzheimer’s Disease, studies of clinical heterogeneity, and research and development of new medications to treat Alzheimer’s Disease. Dr. Doody has served on the Texas Council on Alzheimer’s Disease and Related Disorders, the Board of Directors for the Houston and Southeast Texas Chapter of the Alzheimer’s Association and is listed in Best Doctors in America. She received the Distinguished Alumni Award from Rice University in 2009.

Jeffrey Cummings, MD
Scientific Advisory Board – Clinical Expert
Dr. Jeffrey Cummings is Professor of Neurotherapeutics and Drug Development in the Neurological Institute, Cleveland Clinic. He is Director of the Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada and Cleveland, Ohio. Dr. Jeffrey Cummings graduated magna cum laude from the University of Wyoming, Laramie and obtained his MD degree (with thesis) from the University of Washington, Seattle. He completed internship at Hartford Hospital in Hartford, Connecticut and did his Neurology residency at Boston University, Boston, Massachusetts. Dr. Cummings was formerly the Augustus S. Rose Professor of Neurology and Professor of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine at UCLA, Los Angeles, California, USA. He was the Director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. Dr. Cummings has expertise in neuropsychiatric assessment, outcomes in clinical trials, clinical trial design and analysis, and global clinical trials. He is a frequent consultant to industry. Dr. Cummings has authored more than 500 peer-reviewed papers and 30 books on Alzheimer’s disease, neuropsychiatry, and clinical trials. Dr. Cummings’ interests embrace the neuropsychiatry of neurologic disorders, biomarkers for neurodegenerative diseases, and clinical trials and drug development for neurologic diseases.

Dr. Christopher Shackleton, MD
Scientific Advisory Board – Advisor
Dr. Shackleton is a prominent, uniquely qualified physician and surgeon, clinical investigator, information technologist, and corporate finance/healthcare solutions consultant. He holds triple specialist credentials in medical and surgical disciplines, and has a track record of success as a laboratory and clinical researcher/investigator. In addition, Dr. Shackleton has a strong publication record and is a renowned innovator, pioneer and leader in the development and deployment of new clinical techniques and treatment modalities. In addition to obtaining his medical education and training from the University of British Columbia, University of Toronto and Harvard Medical School, Dr. Shackleton studied corporate finance, financial markets and financial derivatives at The London School of Economics and Political Science and rose to the rank of full professor at the University of California at Los Angeles (UCLA) School of Medicine. He is also on the Board of Trustees of the Fraser Institute.